Clinical Characteristics and Treatment Outcomes in Children, Adolescents, and Young-adults with Hodgkin's Lymphoma: a KPHOG Lymphoma Working-party, Multicenter, Retrospective Study.

Autor:	Lee JM; Department of Pediatrics, Yeungnam University College of Medicine, Daegu, Korea., Choi JY; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.; Seoul National University Cancer Institute, Seoul, Korea., Hong KT; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.; Seoul National University Cancer Institute, Seoul, Korea., Kang HJ; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.; Seoul National University Cancer Institute, Seoul, Korea., Shin HY; Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.; Seoul National University Cancer Institute, Seoul, Korea., Baek HJ; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea., Kook H; Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju, Korea. hoonkook@chonnam.ac.kr., Kim S; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea., Lee JW; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea., Chung NG; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. cngped@catholic.ac.kr., Cho B; Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea., Cho SG; Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea., Park KM; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea., Yang EJ; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea., Lim YT; Department of Pediatrics, Pusan National University School of Medicines, Yangsan, Korea., Suh JK; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Kang SH; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Kim H; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Koh KN; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Im HJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Seo JJ; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea., Cho HW; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Ju HY; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Lee JW; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Yoo KH; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Sung KW; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Koo HH; Department of Pediatrics, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea., Park KD; Department of Pediatrics and Research Institute of Clinical Medicine of Jeonbuk National University-Jeonbuk National University Hospital, Jeonbuk National University Medical School, Jeonju, Korea., Hah JO; Department of Pediatrics, Daegu Fatima Hospital, Daegu, Korea., Kim MK; Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea., Han JW; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea., Hahn SM; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea., Lyu CJ; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea., Shim YJ; Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea., Kim HS; Department of Pediatrics, Keimyung University School of Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea., Do YR; Division of Hemato-oncology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea., Yoo JW; Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, Korea., Lim YJ; Department of Pediatrics, Chungnam National University College of Medicine, Daejeon, Korea., Jeon IS; Department of Pediatrics, Gachon University Gil Medical Center, Incheon, Korea., Chueh HW; Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea., Oh SY; Department of Hematology, Dong-A University Hospital, Busan, Korea., Choi HS; Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea., Park JE; Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea., Lee JA; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Park HJ; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Park BK; Center for Pediatric Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea., Kim SK; Department of Pediatrics, Inha University Hospital, Incheon, Korea., Lim JY; Department of Pediatrics, Gyeongsang National University School of Medicine, Jinju, Korea., Park ES; Department of Pediatrics, Gyeongsang National University School of Medicine, Jinju, Korea., Park SK; Department of Pediatrics, School of Medicine, University of Ulsan, Ulsan, Korea., Choi EJ; Department of Pediatrics, Daegu Catholic University School of Medicine, Daegu, Korea., Choi YB; Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Korea., Yoon JH; Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
Jazyk:	angličtina
Zdroj:	Journal of Korean medical science [J Korean Med Sci] 2020 Nov 30; Vol. 35 (46), pp. e393. Date of Electronic Publication: 2020 Nov 30.
DOI:	10.3346/jkms.2020.35.e393
Abstrakt:	Background: Hodgkin's lymphoma (HL) constitutes 10%-20% of all malignant lymphomas and has a high cure rate (5-year survival, around 90%). Recently, interest has increased concerning preventing secondary complications (secondary cancer, endocrine disorders) in long-term survivors. We aimed to study the epidemiologic features and therapeutic outcomes of HL in children, adolescents, and young adults in Korea. Methods: We performed a multicenter, retrospective study of 224 patients aged < 25 years diagnosed with HL at 22 participating institutes in Korea from January 2007 to August 2016. Results: A higher percentage of males was diagnosed at a younger age. Nodular sclerosis histopathological HL subtype was most common, followed by mixed cellularity subtype. Eighty-one (36.2%), 101 (45.1%), and 42 (18.8%) patients were classified into low, intermediate, and high-risk groups, respectively. Doxorubicin, bleomycin, vinblastine, dacarbazine was the most common protocol (n = 102, 45.5%). Event-free survival rate was 86.0% ± 2.4%, while five-year overall survival (OS) rate was 96.1% ± 1.4%: 98.7% ± 1.3%, 97.7% ± 1.6%, and 86.5% ± 5.6% in the low, intermediate, and high-risk groups, respectively ( P = 0.021). Five-year OS was worse in patients with B-symptoms, stage IV disease, high-risk, splenic involvement, extra-nodal lymphoma, and elevated lactate dehydrogenase level. In multivariate analysis, B-symptoms and extra-nodal involvement were prognostic factors for poor OS. Late complications of endocrine disorders and secondary malignancy were observed in 17 and 6 patients, respectively. Conclusion: This is the first study on the epidemiology and treatment outcomes of HL in children, adolescents, and young adults in Korea. Future prospective studies are indicated to develop therapies that minimize treatment toxicity while maximizing cure rates in children, adolescents, and young adults with HL. Competing Interests: The authors have no potential conflicts of interest to disclose. (© 2020 The Korean Academy of Medical Sciences.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu